Search

Aims: To ascertain the effects of allowable sampling time prior to red cell transfusion when screening for alloantibodies, we compared antibody detection rates and frequencies of delayed hemolytic transfusion reactions (DHTRs) among patients drawn within two weeks versus patients drawn within one week of transfusion. Methods: Alloantibody screening for 32,601 patients from January 1997 through August 2006 was done within two weeks of transfusion, and for 44,896 patients from September 2006 through March 2017 was done within one week. Among transfusion recipients, 6,234 screened within two weeks and 8,066 screened within one week were evaluated for DHTR. Results: Alloantibodies were detected in 1.2% of cases screened within two weeks and in 1.3% of cases screened within one week, with no statistical difference. Anti-Fyb was more frequently detected (115.8 versus 39.9 per 100,000 patients) among those screened within one week (p

Aims: Alloimmune response to red cell transfusion has not been widely investigated in pediatric patients. We retrospectively compared the frequency and specificity of red cell antibody formation among pediatric recipients grouped by age, versus an adult control cohort. Methods: A total of 331 pediatric red cell transfusion recipients were studied in four age groups: 0 to 4.9 months (Group A), 5.0 to 11.9 months (Group B), 1.0 to 5.9 years (Group C), and 6.0 to 14.9 years (Group D). Similarly transfused adult males, 20.0 to 59.9 years old, as a control cohort group. Alloimmunization was defined as post-transfusion detection of red cell alloantibodies not detected prior to transfusion. Results: After red cell transfusion, no one in Group A (0 of 106) developed alloantibodies, whereas 8.0% (2 of 25) in Group B, 1.1% (1 of 95) in Group C, and 2.9% (3 of 105) in Group D, versus 2.1% (8 of 380) of adult male controls who developed alloantibodies. However, these differences did not achieve statistical significance. Conclusion: This investigation of alloimmunization in pediatric recipients found no cases in patients younger than five months old, however, the incidence rates of older age groups were statistically indistinguishable from a control cohort of male adults. Until larger studies suggest otherwise, current antibody screening and cross-matching policies should be continued.

Aims: Clinically significant antibodies may become undetectable and still provoke transfusion reactions. Hemolysis has been reported among transfusion recipients with anti-Kidd that was undetectable by gel column but detectable by other methods. Methods: We compared two automated technologies - microplate (MP) and gel column (GC) methods - with manual methods in ABO/RhD typing, irregular antibody screening, identification, titration, and detection threshold of mixed-field agglutination. Results: Automated systems agreed generally with tube results in 98% or more of ABO forward and RhD groupings, but showed weaker reactions in ABO reverse testing against A1 (K=0.88 with MP and K=0.77 with GC) and B cells (K=0.66 with MP and K=0.68 with GC) and failed to detect some anti-A (2 of 273 samples with MP) and anti-B (2 of 273 with MP and 1 of 272 with GC). MP missed 2 (anti-E and –Fyb) of 8 antibodies and GC missed 5 (2 anti-E and 1 each of -Fyb, -Jka and –Lea) of 10 antibodies, which manual PEG-IAT detected. Among 11 known alloantibodies, MP detected 7 antibodies at higher dilution than tube PEG-IAT, whereas GC showed lower scores in 7 samples than tube PEG-IAT and missed 2 clinically significant antibodies (anti-C and anti-Fyb). Conclusion: Automated systems, comparable to manual tube technique for forward grouping of ABO and RhD, are less sensitive in ABO reverse testing. As GC more often failed to detect clinically significant antibodies of low-titer, users should be especially mindful of possible post-transfusion hemolysis.